CD19 and diffuse large B-cell lymphoma: Although the CD19-directed therapy gains most attention in the treatment of ALL and DLBCL, especially due to the FDA approval of tisagenlecleucel and axicabtagene ciloleucel, there have been studies dedicated to using this compound in the treatment of relapsed and refractory MM.